DeDora Capital Inc. Acquires 451 Shares of Danaher Co. (NYSE:DHR)

DeDora Capital Inc. lifted its stake in Danaher Co. (NYSE:DHR) by 16.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,237 shares of the conglomerate’s stock after purchasing an additional 451 shares during the quarter. DeDora Capital Inc.’s holdings in Danaher were worth $808,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. Cape Investment Advisory Inc. purchased a new position in Danaher in the 4th quarter worth approximately $25,000. BKM Wealth Management LLC purchased a new stake in shares of Danaher during the fourth quarter valued at $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher during the 4th quarter valued at about $29,000. OFI Invest Asset Management bought a new stake in Danaher in the 3rd quarter worth approximately $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Danaher in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. KeyCorp raised their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Finally, Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Danaher Trading Up 0.6 %

Shares of DHR stock traded up $1.54 during trading hours on Friday, reaching $248.38. 1,787,817 shares of the stock were exchanged, compared to its average volume of 2,914,990. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The firm has a market capitalization of $183.97 billion, a price-to-earnings ratio of 42.10, a price-to-earnings-growth ratio of 3.80 and a beta of 0.83. The company’s 50-day moving average price is $248.48 and its 200-day moving average price is $232.27.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the firm posted $2.36 earnings per share. The company’s quarterly revenue was down 2.6% on a year-over-year basis. As a group, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold a total of 107,273 shares of company stock valued at $26,813,819 over the last quarter. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.